Found 1 results
Filters: Author is D.B. Li  [Clear All Filters]
D. B. Li, Wei, X., Jiang, L. H., Wang, Y., and Xu, F., Meta-analysis of epidemiological studies of association of P53 codon 72 polymorphism with bladder cancer, vol. 9, pp. 1599-1605, 2010.
Begg CB and Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101. PMid:7786990   Chen WC, Tsai FJ, Wu JY, Wu HC, et al. (2000). Distributions of p53 codon 72 polymorphism in bladder cancer-proline form is prominent in invasive tumor. Urol. Res. 28: 293-296. PMid:11127705   Dai S, Mao C, Jiang L, Wang G, et al. (2009). p53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Hum. Genet. 125: 633-638. PMid:19357867   Egger M, Davey SG, Schneider M and Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. PMid:9310563 PMCid:2127453   Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991). p53 mutations in human cancers. Science 253: 49-53. PMid:1905840   Horikawa Y, Nadaoka J, Saito M, Kumazawa T, et al. (2008). Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol. Rep. 20: 49-55. PMid:18575717   Ioannidis JP, Boffetta P, Little J, O'Brien TR, et al. (2008). Assessment of cumulative evidence on genetic associations: interim guidelines. Int. J. Epidemiol. 37: 120-132. PMid:17898028   Jemal A, Siegel R, Ward E, Hao Y, et al. (2008). Cancer statistics, 2008. CA Cancer J. Clin. 58: 71-96. PMid:18287387   Kaufman DS, Shipley WU and Feldman AS (2009). Bladder cancer. Lancet 374: 239-249.   Klug SJ, Ressing M, Koenig J, Abba MC, et al. (2009). TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 10: 772-784.   Koushik A, Tranah GJ, Ma J, Stampfer MJ, et al. (2006). p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int. J. Cancer 119: 1863-1868. PMid:16721787   Lee JM, Shun CT, Wu MT, Chen YY, et al. (2006). The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. Mutat. Res. 594: 181-188. PMid:16318864   Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.   Lopez-Beltran A, Escudero AL, Vicioso L, Munoz E, et al. (1996). Human papillomavirus DNA as a factor determining the survival of bladder cancer patients. Br. J. Cancer 73: 124-127. PMid:8554974 PMCid:2074275   Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, et al. (2003). No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann. N. Y. Acad. Sci. 1010: 764-770. PMid:15033824   Maloney KE, Wiener JS and Walther PJ (1994). Oncogenic human papillomaviruses are rarely associated with squamous cell carcinoma of the bladder: evaluation by differential polymerase chain reaction. J. Urol. 151: 360-364. PMid:8283525   Matakidou A, Eisen T and Houlston RS (2003). TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 18: 377-385. PMid:12840112   Murgel de Castro Santos LE, Trindade Guilhen AC, Alves de AR, Garcia SL, et al. (2009). The role of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms in the susceptibility to bladder cancer. Urol. Oncol. (in press). DOI: 10.1016/j.urolonc.2009.03.026.   Rubben H, Lutzeyer W, Fischer N, Deutz F, et al. (1988). Natural history and treatment of low and high risk superficial bladder tumors. J. Urol. 139: 283-285. PMid:3339726   Simoneau M, LaRue H and Fradet Y (1999). Low frequency of human papillomavirus infection in initial papillary bladder tumors. Urol. Res. 27: 180-184. PMid:10422819   Soulitzis N, Sourvinos G, Dokianakis DN and Spandidos DA (2002). p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 179: 175-183.   Sousa H, Santos AM, Pinto D and Medeiros R (2007). Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. Int. J. Mol. Med. 20: 731-741. PMid:17912468   Tommiska J, Eerola H, Heinonen M, Salonen L, et al. (2005). Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin. Cancer Res. 11: 5098-5103. PMid:16033823   Toruner GA, Ucar A, Tez M, Cetinkaya M, et al. (2001). p53 codon 72 polymorphism in bladder cancer - no evidence of association with increased risk or invasiveness. Urol. Res. 29: 393-395. PMid:11828992   Zhou Y, Li N, Zhuang W, Liu GJ, et al. (2007). p53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int. J. Cancer 121: 1481-1486. PMid:17546594